Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study

Ma, Fei; Ouyang, Quchang; Li, Wěi; Jiang, Zefei; Tong, Zhongsheng; Liu, Yunjiang; Li, Huiping; Yu, Shiying; Feng, Jifeng; Wang, Shusen; Hu, Xichun; Zou, Jianjun; Zhu, Xiaoyu; Xu, Binghe

doi:10.1200/jco.19.00108

Public

Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study

Published in Journal of Clinical Oncology • Aug 20, 2019

Authors:

Fei Ma

Quchang Ouyang

Wěi Li

Abstract

PURPOSE Pyrotinib, an irreversible pan-ErbB inhibitor, showed promising antitumor activity and acceptable tolerability in a phase I trial. We assessed the efficacy and tolerability of pyrotinib versus lapatinib, both in combination with capecitabine, in women with human epidermal growth factor recep...

Subject

Capecitabine

Lapatinib

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!